**What's Known**

Demand to survey and predict antimicrobial resistance (AMR) has resulted in the design and implementation of surveillance systems. Minimum data sets are necessary to establish national surveillance systems with consistent core data elements covering all aspects of the domain problem.

**What's New**

Current study provides a set of data elements and a schematic framework for the implementation of an AMR surveillance system, both nationally and globally. Suggested minimum data set is compatible with the WHO GLASS standards and international ontologies and coding systems.

Introduction {#sec1-1}
============

For many years, antimicrobial resistance (AMR) has been a growing threat to the effective treatment and management of a range of infections caused by bacterial pathogens.^[@ref1]^ If no effective plans to combat this resistance are implemented, it is forecast that it will lead to an annual 10 million deaths by 2050.^[@ref2]^ In developing countries, the risk of AMR is growing rapidly.^[@ref3]^ Iran has one of the highest global antibiotic consumptions, and there are concerns that the irresponsible use of antimicrobial agents will result in a high level of AMR.^[@ref4],[@ref5]^ Iran is facing severe antibiotic misuse and overprescription, which is creating a large economic burden. According to a report, antibiotics were used inappropriately in 98% of all procedures.^[@ref6]^ Success of treatment depends on the availability of accurate, reliable, and comprehensive data and knowledge at the point of therapeutic decision-making to identify the origin, spread, and patterns of AMR.^[@ref7]^ The demand to survey and predict such resistance has resulted in the design and implementation of surveillance systems at all geographical levels.^[@ref8],[@ref9]^ A comprehensive and up-to-date surveillance system is a critical requirement in monitoring and controlling AMR trends.^[@ref10]^ Despite the steps taken by countries and organizations to boost monitoring and surveillance, data gaps remain because interoperability between regional levels has yet to be materialized.^[@ref11]^ These gaps, together with a lack of unified standards for data sharing at national and global levels, are hampering efforts to produce knowledge at a global level with a view to enabling a comprehensive surveillance of the occurrence and trends of resistance worldwide.^[@ref12]^ To meet such interoperability challenges, researchers have recommended various AMR control strategies such as the establishment of local, national, and global strategies, surveillance systems, and networks based on harmonized and well-informed efforts across all nations.^[@ref13]^ For the effective and early implementation of antimicrobial resistance surveillance systems (AMRSSs) at a national level, a stepwise approach should be taken in the design and development of software modules. Database design is the first important step in the life-cycle of the information system, and it should be performed in accordance with a proper plan.^[@ref14]^ Minimum data sets (MDSs) facilitate the establishment of national databases with consistent core data elements covering all aspects of the domain problem.^[@ref15]^ Numerous scientific committees that aim to facilitate multidisciplinary and multi-institutional studies have latterly been established. However, irrespective of this aim, a standard method for the collection, analysis, distribution, and reporting of data to other participants is required.^[@ref16]^ Management of AMR data at a national level requires the storage, retrieval, and exchange standards in the MDS of our AMRSS^[@ref17]^ because the identification of an MDS is the most basic task with regard to the data collection of a surveillance system.^[@ref18]^

Unfortunately, there is no national AMRSS in Iran. The Iranian Ministry of Health and Medical Education (MOHME), the Iranian Food and Drug Administration, and public health agencies have emphasized the need for a national AMRSS to improve preventive actions against this increased threat. The identification of a national MDS will support the development and implementation of an effective surveillance system and will provide conceptual interoperability at local, national, and global levels by covering data and standardization gaps based on novel interoperability strategies such as the Global Antimicrobial Resistance Surveillance System (GLASS). Thus, the present study was conducted to provide a comprehensive MDS as a template for establishing an AMRSS.

*Related Works* {#sec1-6}
---------------

There is a paucity of research on the development of an AMRSS MDS due to the short history of AMRSSs. The World Health Organization (WHO) recommended the development and implementation of nationwide surveillance systems to collect, analyze, and report AMR data on behalf of upper regional and global levels, and in 2015 it announced its GLASS to enable countries to create a worldwide picture of AMR by collecting data regarding major pathogens and antimicrobial resistant organisms from their respective national AMRSS.^[@ref19]^ The WHO suggested 7 categories, including identification number, names, gender, dates, hospitalization data, and specimen data.^[@ref12]^

In 2014, the European Antimicrobial Resistance Surveillance Network (EARS-Net) introduced its own MDS to AMRSS in a supra-national manner. The recommended MDS incorporated 53 data elements in 8 categories, consisting of laboratory, patient, date, specimen, technical, and epidemiological data elements.^[@ref20]^ The United States and Australia have a similar approach; they recommended their own MDS in the first phase of their AMRSS development. The United States filtered demographic data due to confidentiality and privacy challenges. Australia introduced 2 distinct MDSs by first developing an AMRSS MDS and then going a step beyond by recommending through the Drug Utilization Sub-Committee a surveillance MDS for antimicrobial drug therapy and management. Now many hospitals contribute data on a voluntary basis to antimicrobial utilization programs.^[@ref21]^ Recently, some other countries have collaborated in developing AMRSSs.^[@ref22],[@ref23]^

Materials and Methods {#sec1-2}
=====================

Our cross-sectional, descriptive study was performed in 2016 at Tehran University of Medical Sciences (TUMS) in Iran. Data were collected from selected pioneering countries and organizations, including the United States,^[@ref24]^ Australia,^[@ref25]^ the WHO,^[@ref26]^ and the European Union,^[@ref27]^ all of which have national or international AMRSSs in place. Related material was retrieved via a literature review. The material encompassed papers, guidelines, strategies, gray documents, reports, types of software, and webpages available on general and specific search engines. Relevant studies were identified via keywords comprising the following: minimum data set, MDS, antimicrobial resistance, standard data, data element, AMR data elements, WHO, EARS-Net, National Antimicrobial Resistance Monitoring System (NARMS), and Australia. Google, Google Scholar, PubMed, ScienceDirect, and Scopus were searched for related keywords. All resources were confirmed from 2000 to May 2016. In this step, no sampling method was used, and all of the literature was evaluated on the basis of the inclusion criteria. The literature review was limited to the English and Persian languages during this period, in the form of full-texts and their valid sources. Materials without full-text access via the TUMS central library were excluded from the study. This process continued until data saturation was achieved. To determine the data saturation point, we conducted a simple interview with 2 key informants: the curator of the National Reference Laboratory and an expert from the Centers for Disease Control and Prevention (CDC). They validated the data elements in a quick and simple process. The collected data elements were classified into basic, clinical, laboratory, electronic reporting, infection control, microbiology, pharmacy, WHO-derived, and other (expert-recommended) data. These data elements were combined with the selected countries and organizations' recommendations in order to construct the final version of the MDS checklist. A questionnaire was designed on the basis of the extracted checklist; it was composed of 3 columns with "yes" and "no" alongside each data element. Expert recommendation data elements were recorded in a blank row. The content validity of the questionnaire was assessed by 6 experts: 2 infectious diseases clinicians, 2 bacteriology specialists, and 2 health information management experts. The inclusion criteria were comprised of having been an expert with national responsibility in AMR stewardship in the preceding 3 years, having a major role in the local Antimicrobial Stewardship Program (ASP), full professorship or associate professorship, and active collaboration in the WHO meetings and programs (e.g., the WHO focal points in AMR surveillance programs). Uninterested experts and nonacademic experts were excluded from the study. Many references have recommended that an ASP team be comprised of 6 to 9 experts with different disciplines related to surveillance (as is the case with the selected team with national responsibilities in Iran). All guidelines on ASP activities have limited the number of experts in the design and development of AMRSS strategies.^[@ref28]^

In the present study, after an initial coordination by telephone, 6 targeted e-mails were sent to the selected experts, who returned a completed checklist to us within a week. The results were aggregated, and the reliability of the questionnaire was evaluated using test-retest at a week's interval by resending a new e-mail in SPSS software. A Spearman correlation coefficient of 78% was achieved.

The ultimate data elements of the AMRSS MDS were determined by using the Delphi technique with the participation of available informants, who were 6 experts from the MOHME, Tehran University of Medical Sciences, Tabriz University of Medical Sciences, and Iran University of Medical Sciences. The demographic features of the informants are shown in [table 1](#T1){ref-type="table"}.

###### 

Demographic features of the experts in the Delphi technique

  Specialty                                  Age      Gender   Academic Level         Job                    Experience
  ------------------------------------------ -------- -------- ---------------------- ---------------------- ------------
  Pediatrics infectious disease fellowship   52       Male     PhD                    MOHME CDC expert       \>15 y
  Infectious disease medicine                40       Male     PhD                    University professor   \>7 y
  Bacteriology expert                        46       Male     PhD                    University professor   \>10 y
  Bacteriology expert                        65       Male     PhD                    University professor   \>25 y
  Health information management expert       Female   PhD      University professor   \>30 y                 
  Health information management expert       35       Male     PhD                    University professor   \>7 y

MOHME: Iranian ministry of health and medical education; CDC: Centers for disease control and prevention

The inclusion and exclusion criteria were the same as those in the previous step. We used a 5-point Likert scale checklist, which allows the respondents to express to what extent they agree or disagree with a particular data element. Data elements with agreement levels of under 50% were excluded, and those with agreement levels of over 75% were accepted as required data elements. Data elements between 50% and 75% were reassessed using the checklist in the second round in a similar manner and elements with greater than 75% agreements were added to the final data elements. The final checklist was distributed by visiting the experts in their personal office.

In the next step, the recommended data elements were mapped to the common international coding systems used in Iran. Finally, adaptation of the recommended MDS to that of other countries was evaluated in the form of a comparative table.

Results {#sec1-3}
=======

The AMRSS data elements were classified into 8 categories. The total number of the ultimate data elements was 144. [Table 2](#T2){ref-type="table"} shows the result of the Delphi technique on the data elements.

###### 

Result of the Delphi technique on the extracted data elements

  Categories                  Number of Data Elements   Delphi First Round   Delphi Second Round   Result                 
  --------------------------- ------------------------- -------------------- --------------------- -------- ---- --- ---- ----
  Basic data                  29                        6                    7                     16       3    0   4    20
  Clinical data               11                        1                    3                     7        1    0   2    9
  EARS-Net data               5                         5                    0                     0        0    0   0    0
  Electronic reporting data   19                        12                   5                     2        2    0   3    5
  Nutrition data              17                        13                   4                     0        4    0   0    0
  Infection control data      8                         0                    3                     5        0    0   3    8
  Microbiology data           19                        3                    7                     9        4    0   3    12
  Drug data                   7                         4                    0                     3        4    0   0    3
  Specimen data               5                         4                    1                     0        1    0   0    0
  WHO-derived data            24                        6                    8                     10       5    0   3    13
  Total                       144                       54                   38                    52       24   0   18   80

EARS Net data: European antimicrobial resistance surveillance network; WHO: World health organization

Through the Delphi technique, we obtained 80 data elements in 8 axes ([table 3](#T3){ref-type="table"}).

###### 

AMRSS data categories and the elements for Iran and related MAKSA coding

  No   Categories                               Data Elements                                                              With an Equivalent Field in GLASS   MAKSA Coding
  ---- ---------------------------------------- -------------------------------------------------------------------------- ----------------------------------- -----------------------------------------------
  1    Basic data                               Country                                                                    \*                                  ISO_3166-1
  2                                             Laboratory                                                                 String                              
  3                                             Identification number (general unique ID, e.g., national code)             \*                                  String
  4                                             Date of birth                                                              Do \_Date                           
  5                                             Age                                                                        \*                                  Derived element - integer
  6                                             Gender                                                                     \*                                  
  7                                             WHO age category                                                           \*                                  WHO standard international age classification
  8                                             Specimen number                                                            String                              
  9                                             Specimen date                                                              \*                                  Do \_Date
  10                                            Specimen type                                                              \*                                  thritaEHR. Specimen type
  11                                            Specimen start and end date                                                Do \_Date                           
  12                                            Reason (unresponsive to treatment, etc.)                                   SCTID: 408773008(SNOMED-CT)         
  13                                            Isolate number                                                             String                              
  14                                            Organism                                                                   \*                                  SCTID: 264395009(SNOMED-CT)
  15                                            Organism type (subgroups)                                                  SCTID: 264395009 (SNOMED-CT)        
  16                                            Beta-lactamase                                                             SCTID: 79744009 (SNOMED-CT)         
  17                                            ESBL                                                                       SCTID: 409799006(SNOMED-CT)         
  18                                            Carbapenem                                                                 String                              
  19                                            MRSA screening test                                                        CPT 901617                          
  20                                            Serotype (in detailed reports)                                             SCTID: 260820006(SNOMED-CT)         
  21   Clinical data                            Date of admission                                                          Do \_Date                           
  22                                            Date of discharge                                                          Do \_Date                           
  23                                            Date of operation                                                          Do \_Date                           
  24                                            Date of ward admission                                                     Do \_Date                           
  25                                            Diagnosis                                                                  ICD-10                              
  26                                            Operation                                                                  ICD-10-CM                           
  27                                            Prior antibiotic therapy                                                   SCTID: 281789004(SNOMED-CT)         
  28                                            Response to treatment                                                      SCTID: 182985004(SNOMED-CT)         
  29                                            Origin (hospital- or community-acquired)                                   \*                                  SCTID: 255396000(SNOMED-CT)
  30   Electronic reporting data (death data)   Date of death                                                              Do \_Date                           
  31                                            Time of death                                                              Do \_Time                           
  32                                            Death speed (diagnosis to death, shows disease severity)                   ICD-10                              
  33                                            Patient address (street, city, and province) or only geographical region   Country divisions                   
  34                                            Specimen site                                                              SCTID: 430304001(SNOMED-CT)         
  35   Infection control                        Bacteremia                                                                 SCTID: 5758002(SNOMED-CT)           
  36                                            Central catheter                                                           SCTID: 52124006(SNOMED-CT)          
  37                                            Urine catheter                                                             SCTID: 20568009(SNOMED-CT)          
  38                                            Ventilator                                                                 SCTID: 706172005(SNOMED-CT)         
  39                                            Nosocomial infection                                                       SCTID: 19168005(SNOMED-CT)          
  40                                            Peripheral catheter                                                        SCTID: 423954007(SNOMED-CT)         
  41                                            Surgical site infection                                                    SCTID: 423954007(SNOMED-CT)         
  42                                            Urinary tract infection                                                    SCTID: 68566005(SNOMED-CT)          
  43   Microbiology data                        ESBL producer                                                              SCTID: 409799006(SNOMED-CT)         
  44                                            Gram stain                                                                 SCTID: 62777006(SNOMED-CT)          
  45                                            H antigen phase 1                                                          SCTID: 115744003(SNOMED-CT)         
  46                                            H antigen phase 2                                                          "                                   
  47                                            Hodge test                                                                 SCTID: 336769001(SNOMED-CT)         
  48                                            Microscopy                                                                 SCTID: 117259009(SNOMED-CT)         
  49                                            O antigen                                                                  SCTID: 23434000 (SNOMED-CT)         
  50                                            Oxacillin screen plate                                                     SCTID: 67466005 (SNOMED-CT)         
  51                                            Urine colony count                                                         SCTID: 104193001 (SNOMED-CT)        
  52                                            Vancomycin screen plate                                                    String                              
  53                                            VRE                                                                        SCTID: 113727004 (SNOMED-CT)        
  54                                            BLNAR                                                                      SCTID: 712679007 (SNOMED-CT)        
  55   Pharmacy data                            Antibiotic treatment                                                       SCTID: 281789004 (SNOMED-CT)        
  56   Start date                               Do \_Date                                                                                                      
  57   End date                                 Do \_Date                                                                                                      
  58   WHO-derived data                         District                                                                   \*                                  Country Divisions
  59                                            Epid No (Unique ID)                                                        \*                                  String
  60                                            Date sent to ref lab                                                       \*                                  Do \_Date
  61                                            Date received in ref lab                                                   \*                                  Do \_Date
  62                                            Date result to the district                                                \*                                  Do \_Date
  63                                            PMN%                                                                       SCTID: 43657008(SNOMED-CT)          
  64                                            Lymphocyte%                                                                SCTID: 409599009 (SNOMED-CT)        
  65                                            Monocyte%                                                                  SCTID: 401100006(SNOMED-CT)         
  66                                            Eosinophil%                                                                SCTID: 71960002(SNOMED-CT)          
  67                                            Leucocytes%                                                                SCTID: 106200001(SNOMED-CT)         
  68                                            RBC                                                                        SCTID: 14089001(SNOMED-CT)          
  69                                            Parasites                                                                  SCTID: 252400008(SNOMED-CT)         
  70                                            User Information                                                           \*                                  string
  71   Expert recommended data                  Underlying disease                                                         ICD-10                              
  72                                            Immunodeficiency                                                           SCTID: 234532001(SNOMED-CT)         
  73                                            History of travel                                                          SCTID: 443846001(SNOMED-CT)         
  74                                            Destination in travel                                                      String                              
  75                                            Length of stay in destination                                              Integer                             
  76                                            Infection exposure history in 2 weeks or more                              ICD-10                              
  77                                            Type of antimicrobial dosage (intravenous or oral)                         SCTID: 18629005(SNOMED-CT)          
  78                                            Cancer complication                                                        ICD-10                              
  79                                            Transfusion history                                                        SCTID: 161664006(SNOMED-CT)         
  80                                            Vaccination history                                                        SCTID: 425457005(SNOMED-CT)         

AMRSS: Antimicrobial resistance surveillance system; GLASS: Global antimicrobial resistance surveillance system; MAKSA: Iranian electronic health record coding system

The AMR data categories were as follows: basic, clinical, electronic reporting, infection control, microbiology, pharmacy, WHO-derived, and expert-recommended data. The required data elements of the WHO GLASS aggregate reports were indicated. Relevance coding was extracted based on the Iranian electronic health record coding system (MAKSA) to facilitate data exchange between various systems in SEPAS middleware.

As is shown in [table 4](#T4){ref-type="table"}, the WHO recommended an MDS for each pathogen (2002).^[@ref29]^ .

###### 

WHO-required data elements in the national reporting of each participant country

  Pathogens           Recommended Minimum Data Set                                  Recommended on GLASS   Iran National AMRSS MDS   NARMS       EARS-Net   AMRU
  ------------------- ------------------------------------------------------------- ---------------------- ------------------------- ----------- ---------- ------
  *E. coli*           Unique identifier                                             \+                     \+                        \+ (O157)   \+         \+
                      Age or date of birth                                          \+                     \+                        \+ (O157)   \+         \+
                      Gender                                                        \+                     \+                        \+ (O157)   \+         \+
                      Health-care facility                                          \-                     \+                        \+ (O157)   \+         \+
                      Care group                                                    \+                     \+                        \+ (O157)   \+         \+
                      Date of admission                                             \+                     \+                        \+ (O157)   \+         \-
                      Type of specimen                                              \+                     \+                        \+ (O157)   \+         \+
                      Test result (R/I/S)                                           \+                     \+                        \+ (O157)   \+         \+
  *K. pneumonia*      Unique identifier                                             \+                     \+                        \-          \+         \+
                      Age or date of birth                                          \+                     \+                        \-          \+         \+
                      Gender                                                        \+                     \+                        \-          \+         \+
                      Health-care facility                                          \-                     \+                        \-          \+         \+
                      Care group                                                    \+                     \+                        \-          \+         \+
                      Date of admission                                             \+                     \+                        \-          \+         \-
                      Type of specimen                                              \+                     \+                        \-          \+         \+
                      Test result (R/I/S)                                           \+                     \+                        \-          \+         \+
                      Presenting symptoms                                           \-                     \+                        \-          \-         \-
                      Predisposing factors (e.g., cancer, travel, catheter, etc.)   \-                     \+                        \-          \-         \-
  *A. baumannii*      Not mentioned                                                 \-                     \+                        \-          \+         \+
  *S. aureus*         Unique identifier                                             \+                     \+                        \-          \+         \+
                      Age or date of birth                                          \+                     \+                        \-          \+         \+
                      Gender                                                        \+                     \+                        \-          \+         \+
                      Health-care facility                                          \-                     \+                        \+                     
                      Care group                                                    \+                     \+                        \-          \+         \+
                      Date of admission                                             \+                     \+                        \-          \+         \-
                      Type of specimen                                              \+                     \+                        \-          \+         \+
                      Test result (R/I/S)                                           \+                     \+                        \-          \+         \+
                      Presenting symptoms                                           \-                     \+                        \-          \-         \-
                      Predisposing factors (e.g., surgery, trauma, etc.)            \-                     \-                        \-                     
                      Method of identification                                      \-                     \+                        \-          \-         \-
  *Shigella*          Unique identifier                                             \+                     \+                        \+          \-         \+
                      Age or date of birth                                          \+                     \+                        \+          \-         \+
                      Gender                                                        \+                     \+                        \+          \-         \+
                      Health-care facility                                          \-                     \+                        \+          \-         \+
                      Care group                                                    \+                     \+                        \+          \-         \+
                      Date of admission                                             \+                     \+                        \+          \-         \-
                      Type of specimen                                              \+                     \+                        \+          \-         \+
                      Test result (R/I/S)                                           \+                     \+                        \+          \-         \+
                      Outcome (death or recovery)                                   \-                     \+                        \+          \-         \-
  *S. pneumonia*      As for Shigella                                               "                      "                         \-          \+         \+
                      Vaccination history                                           \-                     \+                        \-          \-         \-
  *Salmonella spp.*   As for Shigella                                               "                      "                         \+          \-         \+
  *N. gonorrhoeae*    Unique identifier                                             \+                     \+                        \-          \-         \+
                      Age or date of birth                                          \+                     \+                        \-          \-         \+
                      Gender                                                        \+                     \+                        \-          \-         \+
                      Risk behaviors                                                \-                     \-                        \-          \-         \-
                      Date of onset symptoms                                        \-                     \+                        \-          \-         \-
                      Date of specimen                                              \+                     \+                        \-          \-         \+
                      Anatomic site sampled                                         \-                     \+                        \-          \-         \-
                      Test result (R/I/S)                                           \+                     \+                        \-          \-         \+

+Positive result; -Negative result or not surveyed; WHO: World Health Organization; AMRSS: Antimicrobial resistance surveillance system; MDS: Minimal data set; NARMS: National Antimicrobial Resistance Monitoring System; EARS Net data: European Antimicrobial Resistance Surveillance Network

The WHO GLASS-required data elements (2015),^[@ref12]^ EARS-Net data set, NARMS data elements, Australian AMRU (JETACAR), and Iran national AMRSS MDS were compared to assess the compatibility of the selected systems with the WHO standards and GLASS perquisites and to ensure that there were no missing data elements at both national and global levels. These data elements constituted the global report of each participant to the WHO.

The basic data category included some essential identical data, dates, numbers, and organisms, as well as specimens and their types for collection and analysis. If any confidential piece of information was required for policy considerations, it could be accessed by queries across SEPAS authentication web services.

The clinical data category included important dates, diagnosis, operations, details of prior treatments, and responses to those treatments. We obtained free access to the coding systems and imposed no limit on the range of codes. The electronic reporting data category incorporated some important data regarding patient deaths such as date, time, reason, geographical information, and specimen site.

The infection control category consisted of infection source data such as bacteremia and catheter-related infections. These data were extracted from the WHO documents and platforms for AMRSS. Another important category was that of microbiologic data. This category contained specific data relating to the AMR test, as well as detailed qualitative and quantitative relevance data. The pharmacy data category encompassed antibiotic treatment, dosage, dosage interval, start date, and end date, while the WHO-derived data included some data applicable to rural and under-served areas whereby district-wide test samples were forwarded to a reference laboratory with information such as date sent, date received, and date reported. The district data and other data elements such as some laboratory parameters to satisfy the global objectives pursued by the WHO were also included.

The final category included expert recommendations for Iran. They emphasized underlying diseases, immunodeficiency problems, history and destination of travel, and length of stay in neighboring countries. Infection exposure history (whether it was 2 weeks or more), antimicrobial dosage type (intravenous or oral), cancer complications, transfusion history, and vaccination history were the recommended information. Where possible, MAKSA codes were assigned to each data element to meet interoperability requirements and to reduce data redundancy.

Discussion {#sec1-4}
==========

Given the status of antibiotic use in Iran and the lack of effective surveillance, the current study determined the national AMRSS MDS, containing 80 data elements, to collect, analyze, and report AMR indicators. Each data element was mapped to common coding standards and terminologies to facilitate interoperability between various health systems at local, national, and global levels. Another important outcome of the current study was fulfillment of the WHO GLASS guideline in the data infrastructure of the Iranian AMRSS by applying cross-mapping of data elements. These achievements are essential to implement a GLASS-oriented AMRSS.

Kalankesh et al.^[@ref18]^ reported that the identification of an MDS is the most basic task in the data collection of a surveillance system. Our literature review yielded no standard and uniform data collection formats in Iran. The absence of such a format has thwarted efforts to establish an AMRSS and precluded the participation of Iran in the WHO GLASS. For an effective collaboration in international efforts, the data should be uniform. Therefore, it is critical to develop a national AMRSS MDS (linked with the WHO GLASS) as a database infrastructure for collecting, analyzing, sharing, and reporting AMR data in Iran. It was imperative that our study meet a standard set of data elements at local and national levels.

Many countries and organizations have underscored the identification of an MDS in AMR data collection as a key area in a national program.^[@ref30]^ Eurostat is responsible for providing statistical information to the institutions of the European Union and for promoting harmonization of statistical methods across its members. In addition, it seeks to furnish information to policy-makers with 2 fundamental objectives: 1) defining an MDS and 2) developing efficient and effective data collection and analysis methods.^[@ref31]^ About 80% of countries have focused on determining electronic health record-related MDSs. The result of the present study displayed that our suggested MDS was compatible with international frameworks, especially the WHO standards, more than other countries and organizations. The current study is the first research on the implementation of the GLASS since the publication of GLASS documents.^[@ref32]^

MDS definition and implementation is intended to improve the consistency of reporting methods and the interpretability of the reported results, allowing for a better comparison of the published AMR reports and articles, provision of guidance for future research, and fostering of a generation of on-demand knowledge.^[@ref33]^ Our study encompassed these 2 key areas, particularly the identification of an MDS.

SEPAS is a national project that aims to integrate health-related data for each individual to improve data accessibility and efficiency across Iran. In order to manage AMR data at a national level, it was necessary to meet SEPAS storage, retrieval, and exchange standards in our study.^[@ref17]^ SEPAS utilizes some standards and terminology such as ICD-10, SNOMED, ISO13606, SOA, and MAKSA. All software systems should implement these standards to provide interoperability with SEPAS.^[@ref34]^ As an early step in the Iranian national AMRSS, we met these standards at the required level. A schematic view of the application of the MDS in the Iranian National Health System is proposed in [figure 1](#IJMS-43-494-g001.tif){ref-type="fig"}.

![Shows schematic view of the application of a minimum data set (MDS) in the Iranian National Health System.](IJMS-43-494-g001){#IJMS-43-494-g001.tif}

Documentation of data elements at the point of care (when the patient is transferred to another ward, hospital, or city for any reason) would support health-care workers in making decisions concerning patient transfer, health center equipment, and management of the available resources with a view to augmenting interoperability.^[@ref35],[@ref36]^ SEPAS provides this advantage to physicians, health workers, and policy-makers anytime, anywhere. In order to implement conceptual interoperability, health information managers should identify important data elements and create a data dictionary to generate consistency between health-care providers in various disciplines.^[@ref34]^ SEPAS provides this advantage to physicians, health workers, and policy-makers anytime, anywhere. In order to implement conceptual interoperability, health information managers should identify important data elements and create a data dictionary to generate consistency between health-care providers in various disciplines.^[@ref34]^ Accordingly, identification of a national MDS should be compatible with SEPAS.^[@ref37]^ In our study, the equivalent codes of each data element were extracted on the basis of the reference health-coding of Iran.

The WHO emphasizes that, for the successful establishment of AMRSSs, participation at the country level be made as simple as possible. Thus, systems should collect a minimum set of data needed for useful AMR surveillance and follow an evidence-based approach to public health interventions.^[@ref29]^ In the current study, Iranian CDC experts were incorporated in the evaluation group.

Information technology staff is critical to integrating AMR surveillance standards into existing antimicrobial stewardship programs. Facilitating the collection and reporting of antibiotic data in a standard manner is an important task in policy making vis-à-vis stewardship programs.^[@ref38]^ Consequently, integration of a defined MDS in an antimicrobial stewardship program is a task critical to the implementation of an effective data collection, analysis, and reporting process.

The present study has 2 limitations. First, we aimed to determine a national MDS without enhanced surveillance capabilities; thus, a selected team was enough for the defined objectives. To conduct an enhanced surveillance, it is recommended that clinical domain data sets be combined. Definition of an enhanced surveillance MDS requires that a large sample size of domain experts be drawn upon. Second, we were faced with a lack of comparative studies on the axes of the WHO GLASS and related business intelligence capabilities. We seek to overcome this limitation in our next 2 national studies in the future.

Conclusion {#sec1-5}
==========

Creation of an effective antimicrobial stewardship program requires the sound collection, analysis, and reporting of accurate and reliable AMR data. To obtain a clear national picture of AMR statutes in Iran, we need a uniform and consistent data model that satisfies concept interoperability. Definition of a national MDS should meet these requirements as a first step in the establishment of a surveillance database. The present study provides a set of data elements and a schematic framework for the implementation of an AMRSS, both nationally and globally. For the early implementation of the GLASS in Iran, we recommend the development of conceptual models of surveillance systems and the identification of priority values and scales for each data element such as priority pathogens, antimicrobial agents, surveillance methods, and key performance indicators as the next step.
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